Overview

Gender

male

Investor Type

Investment Partner

Olivier Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006.

He invests primarily in European biotechnology and medtech companies as well as some investments in the United States. In addition to Endosense, he serves on the boards of Noxxon Pharma, ProBioDrug, SuperSonic Imagine, Sapiens Steering Brain Stimulation and JenaValve Technologies.

Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France). Before joining EdRIP, Litzka spent six years with 3i's life science venture capital practice, based first in Munich and then in Paris.

In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris.

Litzka holds a Ph.D. in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and did his scientific research work over several years in Munich and Oxford.